309 related articles for article (PubMed ID: 18207114)
1. Current and future uses of neuroimaging for cognitively impaired patients.
Small GW; Bookheimer SY; Thompson PM; Cole GM; Huang SC; Kepe V; Barrio JR
Lancet Neurol; 2008 Feb; 7(2):161-72. PubMed ID: 18207114
[TBL] [Abstract][Full Text] [Related]
2. Imaging of neurodegenerative cognitive and behavioral disorders: practical considerations for dementia clinical practice.
Atri A
Handb Clin Neurol; 2016; 136():971-84. PubMed ID: 27430453
[TBL] [Abstract][Full Text] [Related]
3. Magnetic resonance imaging and positron emission tomography in the diagnosis of neurodegenerative dementias.
Del Sole A; Malaspina S; Magenta Biasina A
Funct Neurol; 2016; 31(4):205-215. PubMed ID: 28072381
[TBL] [Abstract][Full Text] [Related]
4. Clinical impact of (11)C-Pittsburgh compound-B positron emission tomography carried out in addition to magnetic resonance imaging and single-photon emission computed tomography on the diagnosis of Alzheimer's disease in patients with dementia and mild cognitive impairment.
Omachi Y; Ito K; Arima K; Matsuda H; Nakata Y; Sakata M; Sato N; Nakagome K; Motohashi N
Psychiatry Clin Neurosci; 2015 Dec; 69(12):741-51. PubMed ID: 26085054
[TBL] [Abstract][Full Text] [Related]
5. The Role of Neuroimaging in the Assessment of the Cognitively Impaired Elderly.
Kollack-Walker S; Liu CY; Fleisher AS
Neurol Clin; 2017 May; 35(2):231-262. PubMed ID: 28410658
[TBL] [Abstract][Full Text] [Related]
6. Imaging of mild cognitive impairment and early dementia.
Schuff N; Zhu XP
Br J Radiol; 2007 Dec; 80 Spec No 2():S109-14. PubMed ID: 18445740
[TBL] [Abstract][Full Text] [Related]
7. Association between tau deposition and antecedent amyloid-β accumulation rates in normal and early symptomatic individuals.
Tosun D; Landau S; Aisen PS; Petersen RC; Mintun M; Jagust W; Weiner MW;
Brain; 2017 May; 140(5):1499-1512. PubMed ID: 28334939
[TBL] [Abstract][Full Text] [Related]
8. PET imaging of brain amyloid in dementia: a review.
Quigley H; Colloby SJ; O'Brien JT
Int J Geriatr Psychiatry; 2011 Oct; 26(10):991-9. PubMed ID: 21905095
[TBL] [Abstract][Full Text] [Related]
9. [Novel neuroimaging perspectives in the diagnosis of dementia].
Jessen F
Nervenarzt; 2008 Nov; 79 Suppl 3():129-36; quiz 137. PubMed ID: 18830576
[TBL] [Abstract][Full Text] [Related]
10. Contribution of neuroimaging to the diagnosis of Alzheimer's disease and vascular dementia.
Román G; Pascual B
Arch Med Res; 2012 Nov; 43(8):671-6. PubMed ID: 23142262
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of treatment effects in Alzheimer's and other neurodegenerative diseases by MRI and MRS.
Mueller SG; Schuff N; Weiner MW
NMR Biomed; 2006 Oct; 19(6):655-68. PubMed ID: 16986115
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic issues in dementia: neuroimaging as a surrogate marker of disease.
Small GW
J Geriatr Psychiatry Neurol; 2006 Sep; 19(3):180-5. PubMed ID: 16880360
[TBL] [Abstract][Full Text] [Related]
13. [Imaging diagnosis of dementia].
Ishii K
Nihon Rinsho; 2014 Apr; 72(4):681-6. PubMed ID: 24796097
[TBL] [Abstract][Full Text] [Related]
14. Neuroimaging in cerebrovascular disorders: measurement of cerebral physiology after stroke and assessment of stroke recovery.
Mountz JM; Liu HG; Deutsch G
Semin Nucl Med; 2003 Jan; 33(1):56-76. PubMed ID: 12605357
[TBL] [Abstract][Full Text] [Related]
15. Use of functional imaging in Parkinsonism and dementia.
Burn DJ; O'Brien JT
Mov Disord; 2003 Sep; 18 Suppl 6():S88-95. PubMed ID: 14502661
[TBL] [Abstract][Full Text] [Related]
16. Neuroimaging in Alzheimer disease: an evidence-based review.
Kantarci K; Jack CR
Neuroimaging Clin N Am; 2003 May; 13(2):197-209. PubMed ID: 13677801
[TBL] [Abstract][Full Text] [Related]
17. Molecular neuroimaging in degenerative dementias.
Jiménez Bonilla JF; Carril Carril JM
Rev Esp Med Nucl Imagen Mol; 2013; 32(5):301-9. PubMed ID: 23933381
[TBL] [Abstract][Full Text] [Related]
18. Age-specific and sex-specific prevalence of cerebral β-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional study.
Jack CR; Wiste HJ; Weigand SD; Therneau TM; Knopman DS; Lowe V; Vemuri P; Mielke MM; Roberts RO; Machulda MM; Senjem ML; Gunter JL; Rocca WA; Petersen RC
Lancet Neurol; 2017 Jun; 16(6):435-444. PubMed ID: 28456479
[TBL] [Abstract][Full Text] [Related]
19. Positron emission tomography scans obtained for the evaluation of cognitive dysfunction.
Silverman DH; Mosconi L; Ercoli L; Chen W; Small GW
Semin Nucl Med; 2008 Jul; 38(4):251-61. PubMed ID: 18514081
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
